Aosaikang Pharmaceutical
Aosaikang Pharmaceutical is a China-based pharmaceutical company that leads 3 cancer trials in OnCo, testing the anti-CLDN18.2 antibody ASKB589 and the MET inhibitor ASKC202 in non-small-cell lung cancer and advanced solid tumours.
Overview
Aosaikang Pharmaceutical is a research-driven pharmaceutical manufacturer listed in Shenzhen that develops, produces and sells active ingredients and finished medicines in gastroenterology, oncology, anti-infectives and chronic disease. Its site cites China's first injectable proton pump inhibitor as a flagship product and lists clinical-stage innovative candidates including molecular glue degraders. On ClinicalTrials.gov it is the lead sponsor of 3 trials recorded in OnCo (2 in phase 3 or 2/3): NCT04632108 (phase 1/2, A 1/2 Phase Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor...), NCT04143607 (phase 3, ASK120067 Versus Gefitinib as First-line Treatment for EGFRm Locally Advanced or Metast...) and NCT07109531 (phase 3, ASKC202 Combined With Limertinib Versus Platinum-based Chemotherapy in Treatment of Loc...). Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.
Scorecard
All companies- approved products +24
- targets +2
- modalities +4
- regions +6
- registry trials +30
Limertinib is Aosaikang's third-generation EGFR inhibitor, approved in China in 2024 for lung cancer with the T790M resistance mutation after earlier EGFR drugs, and in phase 3 trials for first-line use.
Carboplatin is a platinum chemotherapy that crosslinks DNA; it is part of the standard pre-surgery regimen for triple-negative breast cancer.
Cisplatin is the original platinum chemotherapy, discovered by accident in 1965; it cures testicular cancer and makes radiation work better in cervical and head and neck cancer.
Pemetrexed is the chemotherapy that, with a platinum drug, became the first approved treatment for mesothelioma in 2004, and is still the backbone today.
Similar pages
not linked directly; found by shared links- TrialFirmonertinib Versus Platinum Based Chemotherapy as First-line Treatment for NSCLC With EGFR PACC or EGFR l861q Mutation
Shares Pemetrexed, Cisplatin, Carboplatin, Non-small-cell lung cancer.
- TrialA Study of Osimertinib With or Without Chemotherapy Versus Chemotherapy Alone as Neoadjuvant Therapy for Patients With EGFRm Positive Resectable Non-S
Shares Pemetrexed, Cisplatin, Carboplatin, Non-small-cell lung cancer.
- TrialA Study of Neoadjuvant Chemotherapy Plus Nivolumab Versus Neoadjuvant Chemotherapy Plus Placebo, Followed by Surgical Removal and Adjuvant Treatment With Nivolumab or Placebo for Participants With Surgically Removable Early Stage Non-small Cell Lung Cancer
Shares Pemetrexed, Cisplatin, Carboplatin, Non-small-cell lung cancer.
- TrialStudy of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy
Shares Pemetrexed, Cisplatin, Carboplatin, Non-small-cell lung cancer.
- TrialCombination Therapies With Adagrasib in Patients With Advanced NSCLC With KRAS G12C Mutation
Shares Pemetrexed, Cisplatin, Carboplatin, Non-small-cell lung cancer.
- TrialStudy of BEBT-109 in Subjects With Non-Small Cell Lung Cancer Carrying EGFR Exon 20 Insertion Mutations
Shares Pemetrexed, Cisplatin, Carboplatin, Non-small-cell lung cancer.
- TrialA Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
Shares Pemetrexed, Cisplatin, Carboplatin, Non-small-cell lung cancer.
- TrialA Phase III Study of SKB264 for EGFR Mutant NSCLC Patients
Shares Pemetrexed, Cisplatin, Carboplatin, Non-small-cell lung cancer.